Jump to content

Eileen Shore

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 9H48F (talk | contribs) at 11:35, 17 July 2019 (Importing Wikidata short description: "American medical researcher" (Shortdesc helper)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Eileen M. Shore
Born
Newark, New Jersey[1]
NationalityUS
Known forResearch on connective tissue diseases
Scientific career
FieldsGenetics

Eileen M. Shore is an American medical researcher and geneticist specializing in research of muscoskeletal disorders such as fibrodysplasia ossificans progressiva.

Education

Shore received her bachelor's degree in biology from the University of Notre Dame in 1976. She then earned a Master of Arts in biology at Indiana University in 1978. Subsequently, she received her PhD from the University of Pennsylvania in cell and molecular biology in 1987.[2]

FOP research

Shore undertakes research into fibrodysplasia ossificans progressiva (FOP), a genetic disease that causes bone tissue to form outside the skeleton, known as heterotopic ossification. In 1992, Shore and Frederick Kaplan initiated the FOP Research Laboratory.[3] Kaplan hired Shore because of her experience as a geneticist—she researched fruit fly larvae as a graduate student and studied mammalian embryology as a postdoctoral researcher.[4]

In 2006, Shore and Kaplan published their findings on the genetic mutation that causes FOP[5] as a paper entitled "A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva".[6] The cause of the disease was traced to a single mutation in the activin A receptor, type I gene.[5]

Once the cause of the disease was identified, Shore became involved in efforts to control the disease and its symptoms. In 2016, she was coauthor on a paper that explored the efficacy of a drug on mice with the same genetic mutation. The authors concluded that the drug palovarotene showed promise in preventing heterotopic ossification, stating that there was "clear evidence for its encompassing therapeutic potential".[7]

As of 2015, Kaplan and Shore were the directors of the Center for Research in FOP and Related Disorders. They are considered the "world's foremost experts on FOP".[3]

Awards and honors

Shore has been the recipient of several awards, including:[1][8]

  • Orthopaedic Research and Education Foundation's Johnson and Johnson Research Award (1994)
  • Advances in Mineral Metabolism (AIMM) Young Investigator Award (2000)
  • Johnson & Johnson Focused Giving Award (2002)
  • Alpha Omega Alpha Honor Medical Society Visiting Professor (2008)

Selected publications

  • Shore, Eileen M.; Xu, Meiqi; Feldman, George J.; Fenstermacher, David A.; Cho, Tae-Joon; Choi, In Ho; Connor, J Michael; Delai, Patricia; Glaser, David L.; Lemerrer, Martine; Morhart, Rolf; Rogers, John G.; Smith, Roger; Triffitt, James T.; Urtizberea, J Andoni; Zasloff, Michael; Brown, Matthew A.; Kaplan, Frederick S. (2006). "A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva". Nature Genetics. 38 (5): 525–527. doi:10.1038/ng1783. PMID 16642017.
  • Medici, Damian; Shore, Eileen M.; Lounev, Vitali Y.; Kaplan, Frederick S.; Kalluri, Raghu; Olsen, Bjorn R. (2010). "Conversion of vascular endothelial cells into multipotent stem-like cells". Nature Medicine. 16 (12): 1400–1406. doi:10.1038/nm.2252. PMC 3209716. PMID 21102460.
  • Shafritz, Adam B.; Shore, Eileen M.; Gannon, Francis H.; Zasloff, Michael A.; Taub, Rebecca; Muenke, Maximilian; Kaplan, Frederick S. (1996). "Overexpression of an Osteogenic Morphogen in Fibrodysplasia Ossificans Progressiva". New England Journal of Medicine. 335 (8): 555–561. doi:10.1056/NEJM199608223350804. PMID 8678932.

References

  1. ^ a b "Shore, Eileen M., Ph.D." American Society for Bone and Mineral Research. Retrieved 2 March 2019.
  2. ^ "Eileen M. Shore, Ph.D." Perelman School of Medicine. Retrieved 2 March 2019.
  3. ^ a b Melton, Christin (3 March 2015). "Fibrodysplasia Ossificans Progressiva: Before You Biopsy, Look at the Toes". Rare Disease Report. Retrieved 2 March 2019.
  4. ^ Zimmer, Carl (June 2013). "The Girl Who Turned to Bone". The Atlantic. Retrieved 2 March 2019.
  5. ^ a b University of Pennsylvania School of Medicine (23 April 2006). "Penn researchers discover gene that creates second skeleton". EurekAlert!. Retrieved 2 March 2019.
  6. ^ Shore, Eileen M.; Xu, Meiqi; Feldman, George J.; Fenstermacher, David A.; Cho, Tae-Joon; Choi, In Ho; Connor, J Michael; Delai, Patricia; Glaser, David L.; Lemerrer, Martine; Morhart, Rolf; Rogers, John G.; Smith, Roger; Triffitt, James T.; Urtizberea, J Andoni; Zasloff, Michael; Brown, Matthew A.; Kaplan, Frederick S. (2006). "A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva". Nature Genetics. 38 (5): 525–527. doi:10.1038/ng1783. PMID 16642017.
  7. ^ Chakkalakal, Salin A.; Uchibe, Kenta; Convente, Michael R.; Zhang, Deyu; Economides, Aris N.; Kaplan, Frederick S.; Pacifici, Maurizio; Iwamoto, Masahiro; Shore, Eileen M. (2016). "Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice with the HumanACVR1R206HFibrodysplasia Ossificans Progressiva (FOP) Mutation". Journal of Bone and Mineral Research. 31 (9): 1666–1675. doi:10.1002/jbmr.2820. PMC 4992469. PMID 26896819.
  8. ^ "UPenn Research Team". ifopa. Retrieved 2 March 2019.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Eileen_Shore&oldid=906667707"